Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anouk E Muller

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 25, 2025
Aminoglycoside breakpoints - the EUCAST approach and what this means for the clinicianChristian G Giske, Marlène Amara, Rafael Cantón, et al.
BMC Infectious Diseases|July 13, 2022
Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional studyTim M J Ewoldt, Alan Abdulla, Puck van den Broek, et al.
Antibiotics (Basel, Switzerland)|February 25, 2023
Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?Letao Li, Sebastiaan D T Sassen, Tim M J Ewoldt, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2025
Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driverSanne van den Berg, Marie G L Attwood, Pippa Griffin, et al.
The Journal of Antimicrobial Chemotherapy|July 9, 2018
Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusionWouter van den Bijllaardt, Maarten J Schijffelen, Ron W Bosboom, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 10, 2021
Nitrofurantoin 100 mg versus 50 mg prophylaxis for urinary tract infections, a cohort studyThijs Ten Doesschate, Kelly Hendriks, Cornelis Henri van Werkhoven, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2026
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictionsSanne van den Berg, Marie Attwood, Pippa Griffin, et al.
Pharmaceutics|December 28, 2021
Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill PatientsFemke de Velde, Brenda C M de Winter, Michael N Neely, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2022
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medicationsPerrin Ngougni Pokem, Peter Matzneller, Steven Vervaeke, et al.
Clinical Pharmacology and Therapeutics|August 29, 2024
A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta-Lactamase InhibitionStef Schouwenburg, Fleur M Keij, Gerdien A Tramper-Stranders, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 25, 2025
Aminoglycoside breakpoints - the EUCAST approach and what this means for the clinicianChristian G Giske, Marlène Amara, Rafael Cantón, et al.
BMC Infectious Diseases|July 13, 2022
Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional studyTim M J Ewoldt, Alan Abdulla, Puck van den Broek, et al.
Antibiotics (Basel, Switzerland)|February 25, 2023
Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?Letao Li, Sebastiaan D T Sassen, Tim M J Ewoldt, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2025
Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driverSanne van den Berg, Marie G L Attwood, Pippa Griffin, et al.
The Journal of Antimicrobial Chemotherapy|July 9, 2018
Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusionWouter van den Bijllaardt, Maarten J Schijffelen, Ron W Bosboom, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 10, 2021
Nitrofurantoin 100 mg versus 50 mg prophylaxis for urinary tract infections, a cohort studyThijs Ten Doesschate, Kelly Hendriks, Cornelis Henri van Werkhoven, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2026
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictionsSanne van den Berg, Marie Attwood, Pippa Griffin, et al.
Pharmaceutics|December 28, 2021
Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill PatientsFemke de Velde, Brenda C M de Winter, Michael N Neely, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2022
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medicationsPerrin Ngougni Pokem, Peter Matzneller, Steven Vervaeke, et al.
Clinical Pharmacology and Therapeutics|August 29, 2024
A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta-Lactamase InhibitionStef Schouwenburg, Fleur M Keij, Gerdien A Tramper-Stranders, et al.
Pageof 7